MARKET

ZVRA

ZVRA

Zevra Therapeutics Inc
NASDAQ
8.60
+0.24
+2.87%
After Hours: 8.59 -0.01 -0.12% 17:05 02/06 EST
OPEN
8.53
PREV CLOSE
8.36
HIGH
8.75
LOW
8.48
VOLUME
604.34K
TURNOVER
--
52 WEEK HIGH
13.16
52 WEEK LOW
6.19
MARKET CAP
484.16M
P/E (TTM)
14.55
1D
5D
1M
3M
1Y
5Y
1D
Does New Real-World MIPLYFFA Data Reshape the Bull Case for Zevra Therapeutics (ZVRA)?
Simply Wall St · 1d ago
Zevra Therapeutics (ZVRA) Valuation Check As New MIPLYFFA Data And EMA Filing Draw Fresh Attention
Simply Wall St · 2d ago
Timothy J. Sangiovanni, SVP Finance & Corp Controller, Reports Disposal of Zevra Therapeutics Inc. Common Shares
Reuters · 3d ago
Zevra Therapeutics CCO Joshua Schafer Reports Sale of Common Shares
Reuters · 3d ago
Reaffirming Buy on Zevra: Durable Miplyffa Efficacy and Annuity-Like NPC Revenue Support $26 Target
TipRanks · 4d ago
Zevra Therapeutics Presents Four New Data On MIPLYFFA To Treat Niemann-Pick Disease Type C; Arimoclomol Shown To Be Well-Tolerated
Benzinga · 4d ago
Zevra Therapeutics Announces Positive Real-World Data for MIPLYFFA in Niemann-Pick Disease Type C
Reuters · 4d ago
Zevra Therapeutics präsentiert positive Langzeitdaten zu MIPLYFFA bei Niemann-Pick Typ C
Reuters · 4d ago
More
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Webull offers Zevra Therapeutics Inc stock information, including NASDAQ: ZVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVRA stock methods without spending real money on the virtual paper trading platform.